Cambridge, UK | 1st January 2016.
Isogenica is delighted to announce the strengthening of its management team with the appointment of Dr Guy Hermans as Chief Scientific Officer.
Guy comes to Isogenica after a long and highly productive career at Ablynx in Belgium, where he was mainly involved in generating and realising novel product opportunities, developing new technologies as required. He brings in over a decade of experience in antibody fragment discovery and early development, as well as antibody discovery technology development.
Prior to joining Ablynx, Guy did research in the pathogenesis and immunotherapy of autoimmune and inflammatory disorders, ranging from preclinical in vitro/in vivo target discovery and validation work up to cell-based immunotherapy clinical trials in Multiple Sclerosis patients.
Guy holds a Master’s degree in Biotechnology from the University of Ghent and a PhD in Medicine from the University of Hasselt. He completed postdoctoral training at Stanford University Medical School.